Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
DUBLIN - Investment management firm BlackRock (NYSE:BLK), Inc. has increased its stake in biopharmaceutical company Alkermes (NASDAQ:ALKS) PLC, according to a disclosure filed Thursday with the Irish Takeover Panel.
BlackRock acquired 127,496 additional ordinary shares with voting rights in Alkermes on July 16, bringing its total holdings to 28,128,565 shares, representing 17.05% of the company’s total voting securities.
The transaction was reported under Rule 6 of the Irish Takeover Panel Act’s Substantial Acquisition Rules, which requires disclosure when significant stakes in publicly traded companies are acquired.
The filing, made through the London Stock Exchange (LON:LSEG)’s news service, did not specify the financial terms of the share acquisition or BlackRock’s investment strategy regarding its Alkermes position.
Alkermes, headquartered in Dublin, Ireland, is known for developing treatments for central nervous system disorders, including schizophrenia, depression, and addiction.
The disclosure was signed by Jana Blumenstein on behalf of BlackRock, according to the regulatory filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.